Table 1.
Baseline characteristics.
| LEN + NIVO n = 16 | LEN + PEM n = 13 | All patients n = 29 | |
|---|---|---|---|
| Age(y), mean ± SD | 49 ± 3.87 | 57.5 ± 4.22 | 42.5 ± 3.57 |
| Sex | |||
| Male | 4 | 6 | 10 |
| Female | 12 | 7 | 19 |
| Aetiology | |||
| Hepatitis B | 14 | 10 | 24 |
| Hepatitis C | 1 | 1 | 2 |
| Hepatitis B+C | 1 | 1 | 2 |
| Other | 0 | 1 | 1 |
| Prior treatment | |||
| Hepatectomy | 9 | 6 | 15 |
| Ablation | 3 | 2 | 5 |
| Loco‐regional (TACE/radiation) | 10 | 11 | 21 |
| Previous sorafenib | 16 | 13 | 29 |
| Previous regorafenib | 12 | 10 | 22 |
| Previous Anlotinib | 3 | 5 | 8 |
| LEN+ICIs | |||
| Second‐line | 4 | 3 | 7 |
| Third‐line | 9 | 5 | 14 |
| Fourth‐line | 3 | 5 | 8 |
| Macrovascular invasion | 13 | 11 | 24 |
| Extrahepatic metastasis | 13 | 10 | 23 |
| Child-Pugh stage | |||
| A | 12 | 11 | 23 |
| B | 2 | 2 | 4 |
| C | 2 | 0 | 2 |
| ECOG PS | |||
| 0 | 13 | 10 | 23 |
| 1-2 | 3 | 3 | 6 |
| Alpha‐Fetoprotein | |||
| <400 (IU/ml) | 6 | 7 | 13 |
| ≥400 (IU/ml) | 9 | 6 | 15 |
TACE, Transhepatic arterial chemotherapy embolization; LEN, Lenvatinib; ICIs, Immune checkpoint inhibitors; BCLC, Barcelona Clinical Liver Cancer Stage.